株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌バイオマーカーの世界市場 (2019年~2030年):TMB、MSI、MMR、TIL検査

Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019 - 2030

発行 ROOTS ANALYSIS 商品コード 836183
出版日 ページ情報 英文 390 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
癌バイオマーカーの世界市場 (2019年~2030年):TMB、MSI、MMR、TIL検査 Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019 - 2030
出版日: 2019年04月30日 ページ情報: 英文 390 Pages
概要

当レポートでは、世界の免疫腫瘍学バイオマーカー検査市場について調査し、市場の現況と将来的見通し、今後の予測、地域別動向、市場に参入する企業のプロファイルについてまとめています。

第1章 序論

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 癌免疫療法
  • 腫瘍変異の負担
  • マイクロサテライトの不安定性/ミスマッチ修復欠乏
  • 腫瘍浸潤リンパ球、その他の新規バイオマーカー

第4章 市場の現況

第5章 製品競合分析

第6章 企業プロファイル

  • 概要
  • Foundation Medicine
  • Lal PathLabs
  • NeoGenomics Laboratories
  • Novogene
  • Q2 Solutions
  • Personal Genome Diagnostics
  • Shenzhen Yuce Biotechnology

第7章 パブリケーション分析

第8章 バイオマーカーベース治験の革新的デザイン

第9章 治験分析

  • 概要
  • 方法
  • 治験リスト
  • 治験分析

第10章 市場予測

  • 概要
  • 仮定と予測方法
  • 市場概要
  • バイオマーカータイプ別市場
  • 疾患適応別市場
  • 分析技術別市場
  • 応用分野別市場
  • 地域別市場

第11章 将来の成長機会

第12章 ステークホルダーのニーズ分析

第13章 バリューチェーン分析

第14章 大手製薬会社の展望

第15章 考察

第16章 付録1

第17章 付録2

目次
Product Code: RA100135

Example Insights:

Till date, close to 200 trials, evaluating the expression of novel biomarkers have been registered across different cancer indications, phases of development and geographical locations.

Overview:

Over the last couple of decades, the healthcare market has witnessed the entry of several advanced and effective treatment options for cancer; these include a variety of targeted therapies, immunotherapies and certain anti-cancer vaccines as well. However, clinical cancer research is still plagued by high failure rates, various drug / therapy-related limitations, and treatment-based adverse effects, some of which have proven to be fatal. A prominent concern is associated with deciding the type of treatment option to be used for a specific cancer. Patients suffering from a singular type of cancer, who may be at the same stage of the disease, have been demonstrated to exhibit different molecular profiles, and thereby, may respond differently to recommended drug / therapy types. In order to address this concern, pharmaceutical developers and healthcare professionals have adopted a more personalized approach to disease diagnosis and treatment. Over time, several molecular markers have been identified and characterized, and many have been validated for use in making important treatment-related decisions.

The role of single analyte biomarkers, such as PD-L1, BRAF, and EGFR, has been well-established across multiple cancer indications. However, due to subtle differences in genomic makeup of individual patients, these biomarkers alone have been shown to be insufficient in determining how patients are likely to respond to various drug / therapy types. Advances in biotechnology have enabled the development of several high throughput tools, which have led to the establishment of better biomarkers, based on genome / exome profiles. Novel biomarkers, such as tumor mutation burden (TMB), microsatellite instability (MSI) / mismatch repair (MMR) deficiency, tumor infiltrating lymphocytes (TILs) and certain others, are presently being investigated across numerous clinical studies. Presently, several diagnostics-focused companies have developed / are developing analytical tests for these biomarkers, which are intended to assist physicians in making personalized treatment-related decisions. It is worth highlighting that many big pharmaceutical players have demonstrated interest in this domain and have launched clinical research initiatives to investigate the relevance and applications of multiple novel biomarkers.

Scope of the Report:

The ‘Novel Immuno-Oncology Biomarker Testing Market, 2019-2030’ report features an extensive study of the current landscape and future outlook of the immuno-oncology biomarkers testing market (focusing particularly on TMB, MSI and TILs (CD3+, CD4+, CD8+, FOXP3+)). It provides an in-depth analysis, highlighting the capabilities of the various companies engaged in this domain. Amongst various elements, the report includes:

  • A detailed analysis of ongoing, biomarker-based clinical trials initiated by big pharmaceutical companies, featuring details on immuno-oncology biomarkers and disease indications being investigated, based on trial registration year, phase of development, recruitment status, therapy design and type of cancer therapy.
  • An analysis of the landscape of companies offering testing services for immuno-oncology biomarkers, namely TMB, MSI / MMR and TILs (including CD3+, CD4+, CD8+ and FOXP3+), based on a number of relevant parameters, such as year of establishment, size of employee base, location of headquarters, availability status of the test, biomarkers analyzed, application areas, disease indication(s) evaluated, analytical techniques utilized, turnaround time, sample input and others.
  • An insightful 2X2 representation of the results of a detailed competitiveness analysis of various tests (segregated across different biomarker groups), taking into consideration the supplier power (size of employee base) and specific test related parameters, such as, application area of the test, turnaround time and other key specifications.
  • Elaborate profiles of leading analytical testing service providers focused on immuno-oncology biomarkers (shortlisted based on strength of service portfolio), featuring a brief overview of the company, its financial information (if available), information on biomarker testing related service(s), recent developments and an informed future outlook.
  • A detailed publication analysis of over 180 research articles that have been published since 2016, highlighting the key focus areas of ongoing research activity related to immuno-oncology biomarkers, namely TMB, MSI / MMR and TILs. It highlights the prevalent research trends related to the year of publication, disease indications, analytical technique used for biomarker assessment, and type of cancer therapy evaluated.
  • A comprehensive clinical trial analysis of completed, ongoing and planned studies, focused on the assessment of novel immuno-oncology biomarkers, namely TMB, MSI / MMR and TILs, based on various parameters, such as trial registration year, trial recruitment status, trial phase, trial design, indication(s) evaluated, leading industry and non-industry players, and geographical locations of trials.
  • A discussion on the upcoming opportunities (such as development of companion diagnostics, emerging technologies for biomarker assessment, and others) that are likely to impact the evolution of this market over the coming years.
  • A discussion on various steps involved in development operations of companion diagnostics, namely R&D, clinical evaluation, manufacturing and assembly, negotiations with payers / insurance providers and marketing / sales activities, and the cost requirements across each of the aforementioned stages.
  • A comparative analysis of the needs of different stakeholders (drug developers, diagnostic developers, testing laboratories, physicians, payers and patients) involved in the development of companion diagnostic products.

One of the key objectives of the report was to estimate the existing market size and potential growth opportunities for novel immuno-oncology biomarker testing services over the coming decade. Based on several parameters, we have provided an informed estimate of the likely evolution of this market in the short to mid-term and long term, for the period 2019-2030. In addition, we have provided the likely distribution of the future opportunity based on (A) biomarker (MSI / MMR, TILs, TMB), (B) disease indications (blood cancer, blood cancer, colon cancer, colorectal cancer, lung cancer, melanoma, prostate cancer and others), (C) analytical technique used (immunohistochemistry, next generation sequencing, polymerase chain reaction and others), (D) application area (research use, clinical use, commercial use), and (E) key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry's evolution.

The opinions and insights presented in this study were also influenced by discussions conducted with stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the state of the novel immuno-oncology biomarkers testing market in the short to mid-term and long term.

Chapter 3 provides a brief introduction to cancer immunotherapy and the various types of immunotherapies, including details on their mechanism of action and key advantages. It elaborates on the importance and applications of biomarkers, specifically in determining patients' response towards checkpoint inhibitor-based immunotherapies. The chapter also highlights the key steps involved in the identification of a candidate biomarker, namely biomarker discovery, analytical validation, clinical relevance and clinical utility. In addition, it highlights the need for novel immuno-oncology biomarkers. Further, it includes a discussion on emerging classes of biomarkers, namely TMB, MSI / MMR and others, along with details regarding expression across various indications, analytical assessment methods and factors influencing expression.

Chapter 4 includes a comprehensive market landscape analysis of companies that offer testing services for novel immuno-oncology biomarkers, particularly for checking response towards immunotherapies. The chapter presents detailed analyses on the basis of year of establishment, size of employee base, location of headquarters, availability status of test (available / under development), biomarkers analyzed (TMB, MSI / MMR and TILs (CD3+, CD4+, CD8+ and FOXP3+), application area(s) (clinical use, research use, commercial use and both clinical / research use), disease indication(s) evaluated, analytical technique(s) utilized (immunohistochemistry, next generation sequencing, polymerase chain reaction and others), turnaround time, sample input, number of genes analyzed and type of nucleic acid utilized. The chapter also provides a list of kits / test panels that are currently commercialized for testing of these biomarkers.

Chapter 5 features a comprehensive 2X2 analysis offering a comparative summary of all the tests within each biomarker category that we came across during our research. It compares the competitiveness of tests, by taking into consideration the supplier power (based on size of employee base) and certain test-related parameters, such as, application area of the test (clinical use, research use, commercial use, both clinical and research use), turnaround time, number of genes analyzed, sample input (cancer tissue only, both normal and cancer tissue) and technique utilized for biomarker assessment.

Chapter 6 provides detailed profiles of some of the important immuno-oncology biomarker testing services providers (shortlisted based on strength of service portfolio). Each company profile includes a brief overview of the company, its financial data (if available), information on biomarker testing related service(s), recent developments and an informed future outlook.

Chapter 7 features a detailed publication analysis of over 180 research articles related to immuno-oncology biomarkers including TMB, MSI / MMR and TILs that have been published since 2016. The analysis was done for publications under each biomarker category and takes into consideration several parameters, including year of publication, disease indications, analytical technique on which the study was focused, most popular journal in which the study was published, and type of cancer therapy evaluated.

Chapter 8 provides information on the innovative clinical trial designs being used for conducting biomarker-based studies for oncology drugs. It provides details on the structure of each study design, highlighting their respective advantages and challenges.

Chapter 9 presents a comprehensive clinical trial analysis of completed, ongoing and planned studies involving immuno-oncology biomarkers (TMB, MSI / MMR and TILs). The analysis was done for clinical trials under each biomarker category across various parameters, such as current trial status, trial registration year, trial recruitment status, trial phase, trial design, indication(s) evaluated, leading industry and non-industry players, and geographical locations of trials.

Chapter 10 features a comprehensive market forecast, highlighting the future potential of novel immuno-oncology biomarkers testing services market till 2030. We have segmented the market on the basis of (A) biomarker (MSI / MMR, TILs, TMB), (B) disease indications (blood cancer, blood cancer, colon cancer, colorectal cancer, lung cancer, melanoma, prostate cancer and others), (C) type of analytical technique used (immunohistochemistry, next generation sequencing, polymerase chain reaction and others), (D) application area (research use, clinical use, commercial use), and (E) key geographical regions (North America, Europe, Asia-Pacific / Rest of the World).

Chapter 11 features a detailed discussion on the upcoming opportunities for testing services providers (such as rise in the number of biomarker-based oncology clinical trials, increasing focus on precision medicine, development of companion diagnostic products and others) in this field that are likely to impact the evolution of the market over the coming years.

Chapter 12 provides information on the needs of different stakeholders (drug developers, diagnostic developers, testing laboratories, physicians, payers and patients) involved in the development of companion diagnostic products. The chapter qualitatively assesses the various companion diagnostics-related needs of these stakeholders, highlighting their respective perspectives regarding the importance of each need.

Chapter 13 presents a value chain analysis featuring a discussion on various steps of the development operations, namely R&D development, clinical assessment of the product, manufacturing and assembly, payer negotiation and marketing activities, of a companion diagnostic and the cost requirements across each of the aforementioned stages.

Chapter 14 features a holistic view of ongoing, biomarker-based, oncology-focused clinical trials initiated by big pharmaceutical companies. For the purpose of understanding the prime focus of these players, we looked at the active clinical studies that have been registered post 2016. Further, the clinical trial data was analyzed on the basis of various parameters, such as trial registration year, phase of development, recruitment status, therapy design (monotherapy, combination therapy, multiple monotherapies, multiple combination therapies and, both monotherapies and combination therapies), type of cancer therapy, biomarker(s) evaluated (most popular biomarker, moderately popular biomarker and other biomarkers), disease indication(s) evaluated (most popular indications, moderately popular indications and other indications), and geographical location of the trials. In addition, we looked at the activity of each pharmaceutical player considered for the analysis across multiple aforementioned parameters. The chapter presents the data on cancer therapies that are being evaluated in these trials with information on targeted cancer indication and biomarker.

Chapter 15 is a collection of interview transcript(s) of discussions held with industry stakeholders, wherever the participants didn't request anonymity.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Cancer Immunotherapy
    • 3.2.1. Cancer Immunotherapy Biomarkers
    • 3.2.2. Identification of a Candidate Biomarker
    • 3.2.3. Need for Novel Immuno-Oncology Biomarkers
  • 3.3. Tumor Mutation Burden (TMB)
    • 3.3.1. Overview
    • 3.3.2. Variation of TMB across Multiple Indications
    • 3.3.3. Methods for Measurement of TMB
    • 3.3.4. Factors Affecting Measurement of TMB
    • 3.3.5. Initiatives for Assessment of TMB as a Potential Biomarker
  • 3.4. Microsatellite Instability / Mismatch Repair Deficiency (MSI / MMR)
    • 3.4.1. Overview
    • 3.4.2. Variation of MSI across Multiple Indications
    • 3.4.3. Methods of Measurement of MSI
  • 3.5. Tumor Infiltrating Lymphocytes and Other Novel Biomarkers

4. CURRENT MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Novel Immuno-Oncology Biomarker Testing Services: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Geographical Location
    • 4.2.4. Analysis by Test Availability
    • 4.2.5. Analysis by Type of Biomarker
    • 4.2.6. Analysis by Application Area
    • 4.2.7. Analysis by Disease Indication
    • 4.2.8. Analysis by Analytical Technique Used
    • 4.2.9. Analysis by Turnaround Time
    • 4.2.10. Analysis by Sample Input
    • 4.2.11. Analysis by Nucleic Acid Tested
    • 4.2.12. Key Players: Analysis by Type of Biomarker
  • 4.3. TMB Tests
    • 4.3.1. Analysis by Application Area
    • 4.3.2. Analysis by Disease Indication
    • 4.3.3. Analysis by Analytical Technique Used
    • 4.3.4. Analysis by Turnaround Time
    • 4.3.5. Analysis by Genes Evaluated
    • 4.3.6. Analysis by Sample Input
  • 4.4. MSI / MMR Tests
    • 4.4.1. Analysis by Application Area
    • 4.4.2. Analysis by Disease Indication
    • 4.4.3. Analysis by Analytical Technique Used
    • 4.4.4. Analysis by Turnaround Time
    • 4.4.6. Analysis by Sample Input
  • 4.5. TIL-based Tests
    • 4.5.1. Analysis by Application Area
    • 4.5.2. Analysis by Disease Indication
    • 4.5.3. Analysis by Analytical Technique Used
    • 4.5.4. Analysis by Turnaround Time
    • 4.5.6. Analysis by Sample Input
  • 4.6. Market Landscape Summary: Analysis by Type of Biomarker and Disease Indication

5. PRODUCT COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Product Competitiveness Analysis: Key Assumptions and Methodology
    • 5.2.1. Tests for the Assessment of TMB
    • 5.2.2. Tests for the Assessment of MSI / MMR
    • 5.2.3. Tests for the Assessment of TILs

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Foundation Medicine
    • 6.2.1. Company Overview
    • 6.2.2. Financial Information
    • 6.2.3. Product / Service Portfolio
      • 6.2.3.1. Novel Biomarker Testing Products / Services
        • 6.2.3.1.1. FoundationOne CDx
        • 6.2.3.1.2. FoundationOne Liquid
        • 6.2.3.1.3. FoundationOne Heme
    • 6.2.4. Recent Developments and Future Outlook
  • 6.3. Lal PathLabs
    • 6.3.1. Company Overview
    • 6.3.2. Financial Information
    • 6.3.3. Product / Service Portfolio
      • 6.3.3.1. Novel Biomarker Testing Products / Services
        • 6.3.3.1.1. Microsatellite Instability (MSI) by PCR
        • 6.3.3.1.2. OncoPro NCCN Lung Cancer Panel (*9 Genes *MSI)
        • 6.3.3.1.3. OncoPro Liquid Biopsy 73 Gene Panel with MSI
    • 6.3.4. Recent Developments and Future Outlook
  • 6.4. NeoGenomics Laboratories
    • 6.4.1. Company Overview
    • 6.4.2. Financial Information
    • 6.4.3. Product / Service Portfolio
      • 6.4.3.1. Novel Biomarker Testing Products / Services
        • 6.4.3.1.1. NeoTYPE Discovery Profile for Solid Tumors
        • 6.4.3.1.2. MSI Analysis / MMR Panel by IHC
        • 6.4.3.1.3. MultiOmyx Tumor Infiltrating Lymphocyte Panel
    • 6.4.4. Recent Developments and Future Outlook
  • 6.5. Novogene
    • 6.5.1. Company Overview
    • 6.5.2. Product / Service Portfolio
      • 6.5.2.1. Novel Biomarker Testing Products / Services
        • 6.5.2.1.1. NovoPM Cancer Panel
        • 6.5.2.1.2. NovoPM TMB
        • 6.5.2.1.3. NovoPM bTMB
        • 6.5.2.1.4. NovoPM MSI
    • 6.5.3. Recent Developments and Future Outlook
  • 6.6. Q2 Solutions
    • 6.6.1. Company Overview
    • 6.6.2. Product / Service Portfolio
      • 6.6.2.1. Novel Biomarker Testing Products / Services
        • 6.6.2.1.1. TMB Assay
        • 6.6.2.1.2. MSI Assay
        • 6.6.2.1.3. TILs Testing
    • 6.6.3. Recent Developments and Future Outlook
  • 6.7. Personal Genome Diagnostics
    • 6.7.1. Company Overview
    • 6.7.2. Product / Service Portfolio
      • 6.7.2.1. Novel Biomarker Testing Products / Services
        • 6.7.2.1.1. PGDx elio Tissue Complete Assay
        • 6.7.2.1.2. PlasmaSELECT-R 64
        • 6.7.2.1.3. CancerXOME-R
        • 6.7.2.1.4. CancerSELECT-R 125
        • 6.7.2.1.5. MutatorDETECT
    • 6.7.3. Recent Developments and Future Outlook
  • 6.8. Shenzhen Yuce Biotechnology
    • 6.8.1. Company Overview
    • 6.8.2. Product / Service Portfolio
      • 6.8.2.1. Novel Biomarker Testing Products / Services
        • 6.8.2.1.1. YuceOne Plus
        • 6.8.2.1.2. YuceOne ICIs
        • 6.8.2.1.3. ct-DNA TMB
        • 6.8.2.1.4. Microsatellite (MSI) Test
    • 6.8.3. Recent Developments and Future Outlook

7. PUBLICATION ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Methodology
  • 7.3. Novel Immuno-Oncology Biomarkers: List of Publications
    • 7.3.1. Analysis by Year of Publication, 2016-2019
    • 7.3.2. Analysis by Year of Publication and Type of Biomarker
    • 7.3.3. Analysis by Year of Publication and Disease Indication
    • 7.3.4. Analysis by Year of Publication and Analytical Technique Used
    • 7.3.5. Analysis by Year of Publication and Type of Cancer Therapy
    • 7.3.6. Most Popular Journals
  • 7.5. Publication Analysis: TMB
    • 7.5.1. Analysis by Year of Publication, 2016-2019
    • 7.5.2. Analysis by Disease Indication
    • 7.5.3. Analysis by Analytical Technique Used
    • 7.5.4. Most Popular Journals
    • 7.6. Publication Analysis: MSI / MMR
    • 7.6.1. Analysis by Year of Publication, 2016-2019
    • 7.6.2. Analysis by Disease Indication
    • 7.6.3. Analysis by Analytical Technique Used
    • 7.6.4. Most Popular Journals
  • 7.7. Publication Analysis: TILs
    • 7.7.1. Analysis by Year of Publication, 2016-2019
    • 7.7.2. Analysis by Disease Indication
    • 7.7.3. Analysis by Analytical Technique Used
    • 7.7.4. Most Popular Journals

8. INNOVATIVE DESIGNS FOR BIOMARKER-BASED CLINICAL TRIALS

  • 8.1. Background and Context
  • 8.2. Biomarker-based Clinical Trial Designs
    • 8.2.1. Enrichment Design
    • 8.2.2. All-Comers Design
    • 8.2.3. Mixture / Hybrid Design
    • 8.2.4. Adaptive Design
  • 8.3 Regulatory Considerations

9. CLINICAL TRIAL ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Methodology
  • 9.3. Novel Immuno-Oncology Biomarkers: List of Clinical Trials
  • 9.4. Clinical Trial Analysis: TMB
    • 9.4.1. Analysis by Trial Registration Year
    • 9.4.2. Analysis by Trial Recruitment Status
    • 9.4.3. Analysis by Trial Phase
    • 9.4.4. Analysis by Trial Design
    • 9.4.5. Analysis by Disease Indication
    • 9.4.6. Most Active Players
    • 9.4.7. Analysis by Number of Clinical Trials and Geography
    • 9.4.8. Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
    • 9.4.9. Analysis by Enrolled Patient Population and Geography
    • 9.4.10. Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status
  • 9.5. Clinical Trial Analysis: MSI / MMR
    • 9.5.1. Analysis by Trial Registration Year
    • 9.5.2. Analysis by Trial Recruitment Status
    • 9.5.3. Analysis by Trial Phase
    • 9.5.4. Analysis by Trial Design
    • 9.5.5. Analysis by Disease Indication
    • 9.5.6. Most Active Players
    • 9.5.7. Analysis by Number of Clinical Trials and Geography
    • 9.5.8. Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
    • 9.5.9. Analysis by Enrolled Patient Population and Geography
    • 9.5.10. Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status
  • 9.6. Clinical Trial Analysis: TILs
    • 9.6.1. Analysis by Trial Registration Year
    • 9.6.2. Analysis by Trial Recruitment Status
    • 9.6.3. Analysis by Trial Phase
    • 9.6.4. Analysis by Trial Design
    • 9.6.5. Analysis by Disease Indication
    • 9.6.6. Most Active Players
    • 9.6.7. Analysis by Number of Clinical Trials and Geography
    • 9.6.8. Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
    • 9.6.9. Analysis by Enrolled Patient Population and Geography
    • 9.6.10. Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status
  • 9.7 Clinical Trials Summary: Analysis by Registration Year and Biomarker
  • 9.8 Clinical Trials Summary: Analysis by Registration Year and Disease Indication
  • 9.9 Clinical Trials Summary: Analysis by Phase and Biomarker
  • 9.10 Overall Clinical Trials Summary: Analysis by Phase and Disease Indication

10. MARKET FORECAST

  • 10.1. Chapter Overview
  • 10.2. Key Assumptions and Forecast Methodology
  • 10.3. Global Novel Immuno-Oncology Biomarker Testing Market, 2019-2030
    • 10.3.1. Global Novel Immuno-Oncology Biomarker Testing Market, 2019-2030 (By Value)
    • 10.3.2. Global Novel Immuno-Oncology Biomarker Testing Market, 2019-2030 (By Volume)
  • 10.4. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Type of Biomarker, 2019-2030 (By Value)
    • 10.4.1. Novel Immuno-Oncology Biomarker Testing Market for MSI / MMR (By Value)
    • 10.4.2. Novel Immuno-Oncology Biomarker Testing Market for TILs (By Value)
    • 10.4.3. Novel Immuno-Oncology Biomarker Testing Market for TMB (By Value)
  • 10.5. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Type of Biomarker, 2019-2030 (By Volume)
    • 10.5.1. Novel Immuno-Oncology Biomarker Testing Market for MSI / MMR (By Volume)
    • 10.5.2. Novel Immuno-Oncology Biomarker Testing Market for TILs (By Volume)
    • 10.5.3. Novel Immuno-Oncology Biomarker Testing Market for TMB (By Volume)
  • 10.6. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Disease Indication, 2019-2030 (By Value)
    • 10.6.1. Novel Immuno-Oncology Biomarker Testing Market for Blood Cancer (By Value)
    • 10.6.2. Novel Immuno-Oncology Biomarker Testing Market for Breast Cancer (By Value)
    • 10.6.3. Novel Immuno-Oncology Biomarker Testing Market for Colon Cancer (By Value)
    • 10.6.4. Novel Immuno-Oncology Biomarker Testing Market for Colorectal Cancer (By Value)
    • 10.6.5. Novel Immuno-Oncology Biomarker Testing Market for Lung Cancer (By Value)
    • 10.6.6. Novel Immuno-Oncology Biomarker Testing Market for Melanoma (By Value)
    • 10.6.7. Novel Immuno-Oncology Biomarker Testing Market for Prostate Cancer (By Value)
    • 10.6.8. Novel Immuno-Oncology Biomarker Testing Market for Other Cancer Indications (By Value)
  • 10.7. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Disease Indication, 2019-2030 (By Volume)
    • 10.7.1. Novel Immuno-Oncology Biomarker Testing Market for Blood Cancer (By Volume)
    • 10.7.2. Novel Immuno-Oncology Biomarker Testing Market for Breast Cancer (By Volume)
    • 10.7.3. Novel Immuno-Oncology Biomarker Testing Market for Colon Cancer (By Volume)
    • 10.7.4. Novel Immuno-Oncology Biomarker Testing Market for Colorectal Cancer (By Volume)
    • 10.7.5. Novel Immuno-Oncology Biomarker Testing Market for Lung Cancer (By Volume)
    • 10.7.6. Novel Immuno-Oncology Biomarker Testing Market for Melanoma (By Volume)
    • 10.7.7. Novel Immuno-Oncology Biomarker Testing Market for Prostate (By Volume)
    • 10.7.8. Novel Immuno-Oncology Biomarker Testing Market for Other Cancer Indications (By Volume)
  • 10.8. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Analytical Technique Used, 2019-2030 (By Value)
    • 10.8.1. Novel Immuno-Oncology Biomarker Testing Market for Immunohistochemistry, 2019-2030 (By Value)
    • 10.8.2. Novel Immuno-Oncology Biomarker Testing Market for Next Generation Sequencing, 2019-2030 (By Value)
    • 10.8.3. Novel Immuno-Oncology Biomarker Testing Market in for Polymerase Chain Reaction, 2019-2030 (By Value)
    • 10.8.4. Novel Immuno-Oncology Biomarker Testing Market for Other Analytical Techniques Used, 2019-2030 (By Value)
  • 10.9. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Analytical Technique Used, 2019-2030 (By Volume)
    • 10.9.1. Novel Immuno-Oncology Biomarker Testing Market for Immunohistochemistry, 2019-2030 (By Volume)
    • 10.9.2. Novel Immuno-Oncology Biomarker Testing Market for Next Generation Sequencing, 2019-2030 (By Volume)
    • 10.9.3. Novel Immuno-Oncology Biomarker Testing Market for Polymerase Chain Reaction, 2019-2030 (By Volume)
    • 10.9.4. Novel Immuno-Oncology Biomarker Testing Market for Other Techniques Used, 2019-2030 (By Volume)
  • 10.10. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Application Area, 2019-2030 (By Value)
    • 10.10.1. Novel Immuno-Oncology Biomarker Testing Market for Research Use, 2019-2030 (By Value)
    • 10.10.2. Novel Immuno-Oncology Biomarker Testing Market for Clinical Use, 2019-2030 (By Value)
    • 10.10.3. Novel Immuno-Oncology Biomarker Testing Market for Commercial Use, 2019-2030 (By Value)
  • 10.11. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Application Area, 2019-2030 (By Volume)
    • 10.11.1. Novel Immuno-Oncology Biomarker Testing Market for Research Use, 2019-2030 (By Volume)
    • 10.11.2. Novel Immuno-Oncology Biomarker Testing Market for Clinical Use, 2019-2030 (By Volume)
    • 10.11.3. Novel Immuno-Oncology Biomarker Testing Market in for Commercial Use, 2019-2030 (By Volume)
  • 10.12. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Geography, 2019-2030 (By Value)
    • 10.12.1. Novel Immuno-Oncology Biomarker Testing Market in North America, 2019-2030 (By Value)
    • 10.12.2. Novel Immuno-Oncology Biomarker Testing Market in Europe, 2019-2030 (By Value)
    • 10.12.3. Novel Immuno-Oncology Biomarker Testing Market in Asia Pacific, 2019-2030 (By Value)
    • 10.12.4. Novel Immuno-Oncology Biomarker Testing Market in Rest of the World, 2019-2030 (By Value)
  • 10.13. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Geography, 2019-2030 (By Volume)
    • 10.13.1. Novel Immuno-Oncology Biomarker Testing Market in North America, 2019-2030 (By Volume)
    • 10.13.2. Novel Immuno-Oncology Biomarker Testing Market in Europe, 2019-2030 (By Volume)
    • 10.13.3. Novel Immuno-Oncology Biomarker Testing Market in Asia Pacific, 2019-2030 (By Volume)
    • 10.13.4. Novel Immuno-Oncology Biomarker Testing Market in Rest of the World, 2019-2030 (By Volume)

11. FUTURE GROWTH OPPORTUNITIES

  • 11.1. Chapter Overview
    • 11.1.1. Increasing Focus on Precision Medicine
    • 11.1.2. Rise in Number of Biomarker-based Clinical Trials
    • 11.1.3. Emerging Technologies for Biomarker Assessment
    • 11.1.4. Development of Companion Diagnostic Products
    • 11.1.5. Other Opportunities

12. CASE STUDY: ANALYSIS OF NEEDS OF STAKEHOLDERS IN THE COMPANION DIAGNOSTICS INDUSTRY

  • 12.1. Chapter Overview
  • 12.2. Companion Diagnostics: Needs of Different Stakeholders
  • 12.3. Comparison of Needs of Various Stakeholders
    • 12.3.1. Needs of Drug Developers
    • 12.3.2. Needs of Companion Diagnostics Developers
    • 12.3.3. Needs of Regulatory Authorities
    • 12.3.4. Needs of Testing Laboratories
    • 12.3.5. Needs of Payers / Insurance Providers
    • 12.3.6. Needs of Physicians
    • 12.3.7. Needs of Patients

13. CASE STUDY: ANALYSIS OF VALUE CHAIN IN THE COMPANION DIAGNOSTICS INDUSTRY

  • 13.1. Chapter Overview
  • 13.2. Companion Diagnostics: Components of the Value Chain
  • 13.3. Companion Diagnostics Value Chain: Cost Distribution
    • 13.3.1. Companion Diagnostics Value Chain: Costs Associated with Research and Product Development
    • 13.3.2. Companion Diagnostics Value Chain: Costs Associated with Costs Associated with Manufacturing and Assembly
    • 13.3.3. Companion Diagnostics Value Chain: Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks
    • 13.3.4. Companion Diagnostics Value Chain: Costs Associated with Payer Negotiation and KoL Engagement
    • 13.3.5. Companion Diagnostics Value Chain: Costs Associated with Marketing and Sales

14. CLINICAL TRIALS AND KEY BIOMARKERS: A BIG PHARMA PERSPECTIVE

  • 14.1. Chapter Overview
  • 14.2. Scope and Methodology
  • 14.3. List of Biomarker-based Clinical Trials of Big Pharmaceutical Companies
    • 14.3.1. Analysis by Trial Registration Year
    • 14.3.2. Analysis by Phase of Development
    • 14.3.3. Analysis by Recruitment Status
    • 14.3.4. Analysis by Therapy Design
    • 14.3.5. Analysis by Type of Cancer Therapy
    • 14.3.6. Analysis by Type of Biomarker
      • 14.3.6.1. Analysis by Trial Registration Year and Biomarker
      • 14.3.6.1. Analysis by Phase of Development and Biomarker
    • 14.3.7. Analysis by Disease Indication
      • 14.3.7.1. Analysis by Trial Registration Year and Disease Indication
      • 14.3.7.2. Analysis by Phase of Development and Disease Indication
    • 14.3.8. Geographical Analysis of Clinical Trials
      • 14.3.8.1. Analysis by Number of Clinical Trials and Geography
      • 14.3.8.2. Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
      • 14.3.8.3. Analysis by Enrolled Patient Population and Geography
      • 14.3.8.4. Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status
    • 14.3.9. Analysis of Key Players
      • 14.3.9.1. Key Players: Analysis by Trial Registration Year
      • 14.3.9.1. Key Players: Analysis by Biomarker
      • 14.3.9.1. Key Players: Analysis by Disease Indication

15. EXECUTIVE INSIGHTS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1. Cancer Immunity Cycle
  • Figure 3.2. Cancer Immunotherapies and Affiliated Mechanisms of Action
  • Figure 3.3. Immune Checkpoint Inhibitors and Affiliated Mechanisms of Action
  • Figure 3.4. Evolution of TMB as an Immunotherapy Biomarker
  • Figure 4.1. Novel Immuno-Oncology Biomarker Testing Services: Distribution by Year of Establishment
  • Figure 4.2. Novel Immuno-Oncology Biomarker Testing Services: Distribution by Company Size
  • Figure 4.3. Novel Immuno-Oncology Biomarker Testing Services: Distribution by Geographical Location
  • Figure 4.4. Novel Immuno-Oncology Biomarker Tests: Distribution by Test Availability
  • Figure 4.5. Novel Immuno-Oncology Biomarker Tests: Distribution by Type of Biomarker
  • Figure 4.6. Novel Immuno-Oncology Biomarker Tests: Distribution by Application Area
  • Figure 4.7. Novel Immuno-Oncology Biomarker Tests: Distribution by Disease Indication
  • Figure 4.8. Novel Immuno-Oncology Biomarker Tests: Distribution by Analytical Technique Used
  • Figure 4.9. Novel Immuno-Oncology Biomarker Tests: Distribution by Turnaround Time
  • Figure 4.10. Novel Immuno-Oncology Biomarker Tests: Distribution by Sample Input
  • Figure 4.11. Novel Immuno-Oncology Biomarker Tests: Distribution by Nucleic Acid Tested
  • Figure 4.12. Novel Immuno-Oncology Biomarker Tests: Distribution by Key Players and Type of Biomarker
  • Figure 4.13. TMB Tests: Distribution by Application Area
  • Figure 4.14. TMB Tests: Distribution by Disease Indication
  • Figure 4.15. TMB Tests: Distribution by Analytical Technique Used
  • Figure 4.16. TMB Tests: Distribution by Turnaround Time
  • Figure 4.17. TMB Tests: Distribution by Sample Input
  • Figure 4.18. MSI / MMR Tests: Distribution by Application Area
  • Figure 4.19. MSI / MMR Tests: Distribution by Disease Indication
  • Figure 4.20. MSI / MMR Tests: Distribution by Analytical Technique Used
  • Figure 4.21. MSI / MMR Tests: Distribution by Turnaround Time
  • Figure 4.22. MSI / MMR Tests: Distribution by Sample Input
  • Figure 4.23. TIL-based Tests: Distribution by Application Area
  • Figure 4.24. TIL-based Tests: Distribution by Disease Indication
  • Figure 4.25. TIL-based Tests: Distribution by Analytical Technique Used
  • Figure 4.26. TIL-based Tests: Distribution by Turnaround Time
  • Figure 4.27. TIL-based Tests: Distribution by Sample Input
  • Figure 4.28. Novel Immuno-Oncology Biomarker Tests Summary: Distribution by Biomarker and Disease Indication
  • Figure 5.1. Product Competitiveness Analysis: Tests for the Assessment of TMB
  • Figure 5.2. Product Competitiveness Analysis: Tests for the Assessment of MSI / MMR
  • Figure 5.3. Product Competitiveness Analysis: Tests for the Assessment of TILs
  • Figure 6.1. Foundation Medicine: Annual Revenues, 2014-Q1 2018 (USD Million)
  • Figure 6.2. Foundation Medicine: Product / Service Portfolio
  • Figure 6.3. Product / Service Portfolio: Genomic Testing
  • Figure 6.4. LalPath Labs: Annual Revenues, 2014-2018 (INR Million)
  • Figure 6.5. NeoGenomics Laboratories: Annual Revenues, 2014-2018 (USD Million)
  • Figure 6.6. Product / Service Portfolio: Biomarker Testing
  • Figure 6.7. Novogene: Product / Service Portfolio
  • Figure 6.8. NovoPM Cancer Panel: Process Workflow, Turnaround Time and Sample Requirement
  • Figure 6.9. Q2 Solutions: Product / Service Portfolio
  • Figure 6.10. Personal Genome Diagnostics: Product / Service Portfolio
  • Figure 6.11. Shenzhen Yuce Biotechnology: Product / Service Portfolio
  • Figure 6.12. YuceOne ICIs Test: Clinical Significance
  • Figure 7.1. Publication Analysis: Distribution by Year of Publication, 2016-2019
  • Figure 7.2. Publication Analysis: Distribution by Year of Publication and Type of Biomarker
  • Figure 7.3. Publication Analysis: Distribution by Year of Publication and Disease Indication
  • Figure 7.4. Publication Analysis: Distribution by Year of Publication and Analytical Technique Used
  • Figure 7.5. Publication Analysis: Distribution by Year of Publication and Type of Cancer Therapy
  • Figure 7.6. Publication Analysis: Most Popular Journals
  • Figure 7.7. TMB-focused Publications: Distribution by Year of Publication, 2016-2019
  • Figure 7.8. TMB-focused Publications: Distribution by Disease Indication
  • Figure 7.9. TMB-focused Publications: Distribution by Analytical Technique Used
  • Figure 7.10. TMB-focused Publications: Most Popular Journals
  • Figure 7.11. MSI / MMR-focused Publications: Distribution by Year of Publication, 2016-2019
  • Figure 7.12. MSI / MMR-focused Publications: Distribution by Disease Indication
  • Figure 7.13. MSI / MMR-focused Publications: Distribution by Analytical Technique Used
  • Figure 7.14. MSI / MMR-focused Publications: Most Popular Journals
  • Figure 7.15. TILs-focused Publications: Distribution by Year of Publication, 2016-2019
  • Figure 7.16. TILs-focused Publications: Distribution by Disease Indication
  • Figure 7.17. TILs-focused Publications: Distribution by Analytical Technique Used
  • Figure 7.18. TILs-focused Publications: Most Popular Journals
  • Figure 8.1. Enrichment Clinical Trial Design: Key Process Steps
  • Figure 8.2. All-Comers Clinical Trial Design: Key Process Steps
  • Figure 8.3. Mixture / Hybrid Clinical Trial Design: Key Process Steps
  • Figure 8.4. Adaptive Clinical Trial Design: Key Process Steps
  • Figure 9.1. TMB-focused Clinical Trials: Distribution by Trial Registration Year
  • Figure 9.2. TMB-focused Clinical Trials: Distribution by Trial Recruitment Status
  • Figure 9.3. TMB-focused Clinical Trials: Distribution by Trial Phase
  • Figure 9.4. TMB-focused Clinical Trials: Distribution by Trial Design
  • Figure 9.5. TMB-focused Clinical Trials: Distribution by Disease Indication
  • Figure 9.6. TMB-focused Clinical Trials: Most Active Players
  • Figure 9.7. TMB-focused Clinical Trials: Distribution by Number of Clinical Trials and Geography
  • Figure 9.8. TMB-focused Clinical Trials: Distribution by Number of Clinical Trials, Trial Phase and Recruitment Status
  • Figure 9.9. TMB-focused Clinical Trials: Distribution by Enrolled Patient Population and Geography
  • Figure 9.10. TMB-focused Clinical Trials: Distribution by Enrolled Patient Population, Trial Phase and Recruitment Status
  • Figure 9.11. MSI / MMR-focused Clinical Trials: Distribution by Trial Registration Year
  • Figure 9.12. MSI / MMR-focused Clinical Trials: Distribution by Trial Recruitment Status
  • Figure 9.13. MSI / MMR-focused Clinical Trials: Distribution by Trial Phase
  • Figure 9.14. MSI / MMR-focused Clinical Trials: Distribution by Trial Design
  • Figure 9.15. MSI / MMR-focused Clinical Trials: Distribution by Disease Indication
  • Figure 9.16. MSI / MMR-focused Clinical Trials: Most Active Players
  • Figure 9.17. MSI / MMR-focused Clinical Trials: Distribution by Number of Clinical Trials and Geography
  • Figure 9.18. MSI / MMR-focused Clinical Trials: Distribution by Number of Clinical Trials, Trial Phase and Recruitment Status
  • Figure 9.19. MSI / MMR-focused Clinical Trials: Distribution by Enrolled Patient Population and Geography
  • Figure 9.20. MSI / MMR-focused Clinical Trials: Distribution by Enrolled Patient Population, Trial Phase and Recruitment Status
  • Figure 9.21. TILs-focused Clinical Trials: Distribution by Trial Registration Year
  • Figure 9.22. TILs-focused Clinical Trials: Distribution by Trial Recruitment Status
  • Figure 9.23. TILs-focused Clinical Trials: Distribution by Trial Phase
  • Figure 9.24. TILs-focused Clinical Trials: Distribution by Trial Design
  • Figure 9.25. TILs-focused Clinical Trials: Distribution by Disease Indication
  • Figure 9.26. TILs-focused Clinical Trials: Most Active Players
  • Figure 9.27. TILs-focused Clinical Trials: Distribution by Number of Clinical Trials and Geography
  • Figure 9.28. TILs-focused Clinical Trials: Distribution by Number of Clinical Trials, Trial Phase and Recruitment Status
  • Figure 9.29. TILs-focused Clinical Trials: Distribution by Enrolled Patient Population and Geography
  • Figure 9.30. TILs-focused Clinical Trials: Distribution by Enrolled Patient Population, Trial Phase and Recruitment Status
  • Figure 9.31. Immuno-Oncology Biomarker-Focused Clinical Trials: Distribution by Trial Registration Year and Biomarker
  • Figure 9.32. Immuno-Oncology Biomarker-Focused Clinical Trials: Distribution by Trial Registration Year and Disease Indication
  • Figure 9.33. Immuno-Oncology Biomarker-Focused Clinical Trials: Distribution by Trial Phase and Biomarker
  • Figure 9.34. Immuno-Oncology Biomarker-Focused Clinical Trials: Distribution by Trial Phase and Disease Indication
  • Figure 10.1. Global Novel Immuno-Oncology Biomarker Testing Market, 2019-2030 (USD Million)
  • Figure 10.2. Global Novel Immuno-Oncology Biomarker Testing Market, 2019-2030 (Units, Million)
  • Figure 10.3. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Type of Biomarker, 2019-2030 (USD Million)
  • Figure 10.4. Novel Immuno-Oncology Biomarker Testing Market for MSI / MMR, 2019-2030 (USD Million)
  • Figure 10.5. Novel Immuno-Oncology Biomarker Testing Market for TILs, 2019-2030(USD Million)
  • Figure 10.6. Novel Immuno-Oncology Biomarker Testing Market for TMB, 2019-2030 (USD Million)
  • Figure 10.7. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Type of Biomarker, 2019-2030 (Units, Million)
  • Figure 10.8. Novel Immuno-Oncology Biomarker Testing Market for MSI / MMR, 2019-2030 (Units, Million)
  • Figure 10.9. Novel Immuno-Oncology Biomarker Testing Market for TILs, 2019-2030(Units, Million)
  • Figure 10.10. Novel Immuno-Oncology Biomarker Testing Market for TMB, 2019-2030 (Units, Million)
  • Figure 10.11. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Disease Indication, 2019-2030 (USD Million)
  • Figure 10.12. Novel Immuno-Oncology Biomarker Testing Market for Blood Cancer, 2019-2030 (USD Million)
  • Figure 10.13. Novel Immuno-Oncology Biomarker Testing Market for Breast Cancer, 2019-2030 (USD Million)
  • Figure 10.14. Novel Immuno-Oncology Biomarker Testing Market for Colon Cancer, 2019-2030 (USD Million)
  • Figure 10.15. Novel Immuno-Oncology Biomarker Testing Market for Colorectal Cancer, 2019-2030 (USD Million)
  • Figure 10.16. Novel Immuno-Oncology Biomarker Testing Market for Lung Cancer, 2019-2030 (USD Million)
  • Figure 10.17. Novel Immuno-Oncology Biomarker Testing Market for Melanoma, 2019-2030 (USD Million)
  • Figure 10.18. Novel Immuno-Oncology Biomarker Testing Market for Prostate Cancer, 2019-2030 (USD Million)
  • Figure 10.19. Novel Immuno-Oncology Biomarker Testing Market for Other Cancer Indications, 2019-2030 (USD Million)
  • Figure 10.20. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Disease Indication, 2019-2030 (Units, Million)
  • Figure 10.21. Novel Immuno-Oncology Biomarker Testing Market for Blood Cancer, 2019-2030 (Units, Million)
  • Figure 10.22. Novel Immuno-Oncology Biomarker Testing Market for Breast Cancer, 2019-2030 (Units, Million)
  • Figure 10.23. Novel Immuno-Oncology Biomarker Testing Market for Colon Cancer, 2019-2030 (Units, Million)
  • Figure 10.24. Novel Immuno-Oncology Biomarker Testing Market for Colorectal Cancer, 2019-2030 (Units, Million)
  • Figure 10.25. Novel Immuno-Oncology Biomarker Testing Market for Lung Cancer, 2019-2030 (Units, Million)
  • Figure 10.26. Novel Immuno-Oncology Biomarker Testing Market for Melanoma, 2019-2030 (Units, Million)
  • Figure 10.27. Novel Immuno-Oncology Biomarker Testing Market for Prostate Cancer, 2019-2030 (Units, Million)
  • Figure 10.28. Novel Immuno-Oncology Biomarker Testing Market for Other Cancer Indications, 2019-2030 (Units, Million)
  • Figure 10.29. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Analytical Technique Used, 2019-2030 (USD Million)
  • Figure 10.30. Novel Immuno-Oncology Biomarker Testing Market for Next Generation Sequencing, 2019-2030 (USD Million)
  • Figure 10.31. Novel Immuno-Oncology Biomarker Testing Market for Polymerase Chain Reaction, 2019-2030 (USD Million)
  • Figure 10.32. Novel Immuno-Oncology Biomarker Testing Market for Immunohistochemistry, 2019-2030 (USD Million)
  • Figure 10.33. Novel Immuno-Oncology Biomarker Testing Market for Other Techniques Used, 2019-2030 (USD Million)
  • Figure 10.34. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Analytical Technique Used, 2019-2030 (Units, Million)
  • Figure 10.35. Novel Immuno-Oncology Biomarker Testing Market for Next Generation Sequencing, 2019-2030 (Units Million)
  • Figure 10.36. Novel Immuno-Oncology Biomarker Testing Market for Polymerase Chain Reaction, 2019-2030 (Units Million)
  • Figure 10.37. Novel Immuno-Oncology Biomarker Testing Market for Immunohistochemistry, 2019-2030 (Units Million)
  • Figure 10.38. Novel Immuno-Oncology Biomarker Testing Market for Other Techniques Used, 2019-2030 (Units Million)
  • Figure 10.39. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Application Area, 2019-2030 (USD Million)
  • Figure 10.40. Novel Immuno-Oncology Biomarker Testing Market for Research Use, 2019-2030 (USD Million)
  • Figure 10.41. Novel Immuno-Oncology Biomarker Testing Market for Clinical Use, 2019-2030 (USD Million)
  • Figure 10.42. Novel Immuno-Oncology Biomarker Testing Market for Commercial Use, 2019-2030 (USD Million)
  • Figure 10.43. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Application Area, 2019-2030 (Units, Million)
  • Figure 10.44. Novel Immuno-Oncology Biomarker Testing Market for Research Use, 2019-2030 (Units, Million)
  • Figure 10.45. Novel Immuno-Oncology Biomarker Testing Market for Clinical Use, 2019-2030 (Units, Million)
  • Figure 10.46. Novel Immuno-Oncology Biomarker Testing Market for Commercial Use, 2019-2030 (Units, Million)
  • Figure 10.47. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Geography, 2019-2030 (USD Million)
  • Figure 10.48. Novel Immuno-Oncology Biomarker Testing Market in North America, 2019-2030 (USD Million)
  • Figure 10.49. Novel Immuno-Oncology Biomarker Testing Market in Europe, 2019-2030 (USD Million)
  • Figure 10.50. Novel Immuno-Oncology Biomarker Testing Market in Asia-Pacific, 2019-2030 (USD Million)
  • Figure 10.51. Novel Immuno-Oncology Biomarker Testing Market in Rest of the World, 2019-2030 (USD Million)
  • Figure 10.52. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Geography, 2019-2030 (Units, Million)
  • Figure 10.53. Novel Immuno-Oncology Biomarker Testing Market in North America, 2019-2030 (Units, Million)
  • Figure 10.54. Novel Immuno-Oncology Biomarker Testing Market in Europe, 2019-2030 (Units, Million)
  • Figure 10.55. Novel Immuno-Oncology Biomarker Testing Market in Asia-Pacific, 2019-2030 (Units, Million)
  • Figure 10.56. Novel Immuno-Oncology Biomarker Testing Market in Rest of the World, 2019-2030 (Units, Million)
  • Figure 11.1. Novel Immuno-Oncology Biomarker Testing: Future Growth Opportunities
  • Figure 12.1. Stakeholder Needs Analysis: Comparison of Needs of Different Stakeholders
  • Figure 12.2. Stakeholder Needs Analysis: Comparison of Needs of Companion Diagnostics Developers
  • Figure 12.3. Stakeholder Needs Analysis: Needs of Regulatory Authorities
  • Figure 12.4. Stakeholder Needs Analysis: Needs of Testing Laboratories
  • Figure 12.5. Stakeholder Needs Analysis: Needs of Payers / Insurance Providers
  • Figure 12.6. Stakeholder Needs Analysis: Needs of Physicians
  • Figure 12.7. Stakeholder Needs Analysis: Needs of Patients
  • Figure 13.1. Companion Diagnostics Development: Primary Operations
  • Figure 13.2. Companion Diagnostics Development: Components of the Value Chain
  • Figure 13.3. Companion Diagnostics Value Chain: Cost Contribution
  • Figure 13.4. Companion Diagnostics Value Chain: Cost Associated with Research and Product Development
  • Figure 13.5. Companion Diagnostics Value Chain: Costs Associated with Manufacturing and Assembly
  • Figure 13.6. Companion Diagnostics Value Chain: Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks
  • Figure 13.7. Companion Diagnostics Value Chain: Costs Associated with Patient Negotiation and KoL Engagement
  • Figure 13.8. Companion Diagnostics Value Chain: Costs Associated with Marketing and Sales
  • Figure 14.1. Biomarker-based Clinical Trials of Big Pharmaceutical Companies: Cumulative Distribution by Trial Registration Year, 2016-2019
  • Figure 14.2. Clinical Trial Analysis: Distribution by Trial Registration Year and Biomarker
  • Figure 14.3. Clinical Trial Analysis: Distribution by Trial Registration Year and Disease Indication
  • Figure 14.4. Clinical Trial Analysis: Distribution by Phase of Development
  • Figure 14.5. Clinical Trial Analysis: Distribution by Trial Phase and Biomarker
  • Figure 14.6. Clinical Trial Analysis: Distribution by Trial Phase and Disease Indication
  • Figure 14.7. Clinical Trial Analysis: Distribution by Recruitment Status
  • Figure 14.8. Clinical Trial Analysis: Distribution by Therapy Design
  • Figure 14.9. Clinical Trial Analysis: Overall Distribution by Biomarkers
  • Figure 14.10. Clinical Trial Analysis: Distribution by Type of Cancer Therapy
  • Figure 14.11. Clinical Trial Analysis: Most Active Players
  • Figure 14.12. Clinical Trial Analysis: Geographical Distribution by Number of Trials
  • Figure 14.13. Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
  • Figure 14.14. Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status

List of Tables

  • Table 3.1. List of Currently Approved Predictive Biomarkers
  • Table 4.1. Novel Immuno-Oncology Biomarker Testing Services: Information on Type of Biomarker Assessed and Test Availability
  • Table 4.2. Novel Immuno-Oncology Biomarker Tests: Information on Key Test Specifications
  • Table 6.1. Novel Immuno-Oncology Biomarker Testing Services: List of Companies Profiled
  • Table 6.2. Foundation Medicine: Recent Developments and Future Outlook
  • Table 6.3. LalPath Labs: Recent Developments and Future Outlook
  • Table 6.4. NeoGenomics Laboratories: Recent Developments and Future Outlook
  • Table 6.5. Novogene: Recent Developments and Future Outlook
  • Table 6.6. Q2 Solutions: Recent Developments and Future Outlook
  • Table 6.7. Personal Genome Diagnostics: Recent Developments and Future Outlook
  • Table 6.8. Shenzhen Yuce Biotechnology: Recent Developments and Future Outlook
  • Table 16.1. Novel Immuno-Oncology Biomarker Testing Services: Distribution by Year of Establishment
  • Table 16.2. Novel Immuno-Oncology Biomarker Testing Services: Distribution by Company Size
  • Table 16.3. Novel Immuno-Oncology Biomarker Testing Services: Distribution by Geographical Location
  • Table 16.4. Novel Immuno-Oncology Biomarker Tests: Distribution by Test Availability
  • Table 16.5. Novel Immuno-Oncology Biomarker Tests: Distribution by Type of Biomarker
  • Table 16.6. Novel Immuno-Oncology Biomarker Tests: Distribution by Application Area
  • Table 16.7. Novel Immuno-Oncology Biomarker Tests: Distribution by Disease Indication
  • Table 16.8. Novel Immuno-Oncology Biomarker Tests: Distribution by Analytical Technique Used
  • Table 16.9. Novel Immuno-Oncology Biomarker Tests: Distribution by Turnaround Time
  • Table 16.10. Novel Immuno-Oncology Biomarker Tests: Distribution by Sample Input
  • Table 16.11. Novel Immuno-Oncology Biomarker Tests: Distribution by Nucleic Acid Tested
  • Table 16.12. Novel Immuno-Oncology Biomarker Tests: Distribution by Key Players and Type of Biomarker
  • Table 16.13. TMB Tests: Distribution by Application Area
  • Table 16.14. TMB Tests: Distribution by Disease Indication
  • Table 16.15. TMB Tests: Distribution by Analytical Technique Used
  • Table 16.16. TMB Tests: Distribution by Turnaround Time
  • Table 16.17. TMB Tests: Distribution by Sample Input
  • Table 16.18. MSI / MMR Tests: Distribution by Application Area
  • Table 16.19. MSI / MMR Tests: Distribution by Disease Indication
  • Table 16.20. MSI / MMR Tests: Distribution by Analytical Technique Used
  • Table 16.21. MSI / MMR Tests: Distribution by Turnaround Time
  • Table 16.22. MSI / MMR Tests: Distribution by Sample Input
  • Table 16.23. TIL-based Tests: Distribution by Application Area
  • Table 16.24. TIL-based Tests: Distribution by Disease Indication
  • Table 16.25. TIL-based Tests: Distribution by Analytical Technique Used
  • Table 16.26. TIL-based Tests: Distribution by Turnaround Time
  • Table 16.27. TIL-based Tests: Distribution by Sample Input
  • Table 16.28. Novel Immuno-Oncology Biomarker Tests Summary: Distribution by Biomarker and Disease Indication
  • Table 16.29. Foundation Medicine: Annual Revenues, 2014-Q1 2018 (USD Million)
  • Table 16.30. LalPath Labs: Annual Revenues, 2014-2018 (INR Million)
  • Table 16.31. NeoGenomics Laboratories: Annual Revenues, 2014-2018 (USD Million)
  • Table 16.32. Publication Analysis: Distribution by Year of Publication, 2016-2019
  • Table 16.33. Publication Analysis: Distribution by Year of Publication and Type of Biomarker
  • Table 16.34. Publication Analysis: Distribution by Year of Publication and Disease Indication
  • Table 16.35. Publication Analysis: Distribution by Year of Publication and Analytical Technique Used
  • Table 16.36. Publication Analysis: Distribution by Year of Publication and Type of Cancer Therapy
  • Table 16.37. Publication Analysis: Most Popular Journals
  • Table 16.38. TMB-focused Publications: Distribution by Year of Publication, 2016-2019
  • Table 16.39. TMB-focused Publications: Distribution by Disease Indication
  • Table 16.40. TMB-focused Publications: Distribution by Analytical Technique Used
  • Table 16.41. TMB-focused Publications: Most Popular Journals
  • Table 16.42. MSI / MMR-focused Publications: Distribution by Year of Publication, 2016-2019
  • Table 16.43. MSI / MMR-focused Publications: Distribution by Disease Indication
  • Table 16.44. MSI / MMR-focused Publications: Distribution by Analytical Technique Used
  • Table 16.45. MSI / MMR-focused Publications: Most Popular Journals
  • Table 16.46. TILs-focused Publications: Distribution by Year of Publication, 2016-2019
  • Table 16.47. TILs-focused Publications: Distribution by Disease Indication
  • Table 16.48. TILs-focused Publications: Distribution by Analytical Technique Used
  • Table 16.49. TILs-focused Publications: Most Popular Journals
  • Table 16.50. TMB-focused Clinical Trials: Distribution by Trial Registration Year
  • Table 16.51. TMB-focused Clinical Trials: Distribution by Trial Recruitment Status
  • Table 16.52. TMB-focused Clinical Trials: Distribution by Trial Phase
  • Table 16.53. TMB-focused Clinical Trials: Distribution by Trial Design
  • Table 16.54. TMB-focused Clinical Trials: Distribution by Disease Indication
  • Table 16.55. TMB-focused Clinical Trials: Most Active Players
  • Table 16.56. TMB-focused Clinical Trials: Distribution by Number of Clinical Trials and Geography
  • Table 16.57. TMB-focused Clinical Trials: Distribution by Number of Clinical Trials, Trial Phase and Recruitment Status
  • Table 16.58. TMB-focused Clinical Trials: Distribution by Enrolled Patient Population and Geography
  • Table 16.59. TMB-focused Clinical Trials: Distribution by Enrolled Patient Population, Trial Phase and Recruitment Status
  • Table 16.60. MSI / MMR-focused Clinical Trials: Distribution by Trial Registration Year
  • Table 16.61. MSI / MMR-focused Clinical Trials: Distribution by Trial Recruitment Status
  • Table 16.62. MSI / MMR-focused Clinical Trials: Distribution by Trial Phase
  • Table 16.63. MSI / MMR-focused Clinical Trials: Distribution by Trial Design
  • Table 16.64. MSI / MMR-focused Clinical Trials: Distribution by Disease Indication
  • Table 16.65. MSI / MMR-focused Clinical Trials: Most Active Players
  • Table 16.66. MSI / MMR-focused Clinical Trials: Distribution by Number of Clinical Trials and Geography
  • Table 16.67. MSI / MMR-focused Clinical Trials: Distribution by Number of Clinical Trials, Trial Phase and Recruitment Status
  • Table 16.68. MSI / MMR-focused Clinical Trials: Distribution by Enrolled Patient Population and Geography
  • Table 16.69. MSI / MMR-focused Clinical Trials: Distribution by Enrolled Patient Population, Trial Phase and Recruitment Status
  • Table 16.70. TILs-focused Clinical Trials: Distribution by Trial Registration Year
  • Table 16.71. TILs-focused Clinical Trials: Distribution by Trial Recruitment Status
  • Table 16.72. TILs-focused Clinical Trials: Distribution by Trial Phase
  • Table 16.73. TILs-focused Clinical Trials: Distribution by Trial Design
  • Table 16.74. TILs-focused Clinical Trials: Distribution by Disease Indication
  • Table 16.75. TILs-focused Clinical Trials: Most Active Players
  • Table 16.76. TILs-focused Clinical Trials: Distribution by Number of Clinical Trials and Geography
  • Table 16.77. TILs-focused Clinical Trials: Distribution by Number of Clinical Trials, Trial Phase and Recruitment Status
  • Table 16.78. TILs-focused Clinical Trials: Distribution by Enrolled Patient Population and Geography
  • Table 16.79. TILs-focused Clinical Trials: Distribution by Enrolled Patient Population, Trial Phase and Recruitment Status
  • Table 16.80. Immuno-Oncology Biomarker-Focused Clinical Trials: Distribution by Trial Registration Year and Biomarker
  • Table 16.81. Immuno-Oncology Biomarker-Focused Clinical Trials: Distribution by Trial Registration Year and Disease Indication
  • Table 16.82. Immuno-Oncology Biomarker-Focused Clinical Trials: Distribution by Trial Phase and Biomarker
  • Table 16.83. Immuno-Oncology Biomarker-Focused Clinical Trials: Distribution by Trial Phase and Disease Indication
  • Table 16.84. Global Novel Immuno-Oncology Biomarker Testing Market, 2019-2030 (USD Million)
  • Table 16.85. Global Novel Immuno-Oncology Biomarker Testing Market, 2019-2030 (Units, Million)
  • Table 16.86. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Type of Biomarker, 2019-2030 (USD Million)
  • Table 16.87. Novel Immuno-Oncology Biomarker Testing Market for MSI / MMR, 2019-2030 (USD Million)
  • Table 16.88. Novel Immuno-Oncology Biomarker Testing Market for TILs, 2019-2030 (USD Million)
  • Table 16.89. Novel Immuno-Oncology Biomarker Testing Market for TMB, 2019-2030 (USD Million)
  • Table 16.90. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Type of Biomarker, 2019-2030 (Units, Million)
  • Table 16.91. Novel Immuno-Oncology Biomarker Testing Market for MSI / MMR, 2019-2030 (Units, Million)
  • Table 16.92. Novel Immuno-Oncology Biomarker Testing Market for TILs, 2019-2030 (Units, Million)
  • Table 16.93. Novel Immuno-Oncology Biomarker Testing Market for TMB, 2019-2030 (Units, Million)
  • Table 16.94. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Disease Indication, 2019-2030 (USD Million)
  • Table 16.95. Novel Immuno-Oncology Biomarker Testing Market for Blood Cancer, 2019-2030 (USD Million)
  • Table 16.96. Novel Immuno-Oncology Biomarker Testing Market for Breast Cancer, 2019-2030 (USD Million)
  • Table 16.97. Novel Immuno-Oncology Biomarker Testing Market for Colon Cancer, 2019-2030 (USD Million)
  • Table 16.98. Novel Immuno-Oncology Biomarker Testing Market for Colorectal Cancer, 2019-2030 (USD Million)
  • Table 16.99. Novel Immuno-Oncology Biomarker Testing Market for Lung Cancer, 2019-2030 (USD Million)
  • Table 16.100. Novel Immuno-Oncology Biomarker Testing Market for Melanoma, 2019-2030 (USD Million)
  • Table 16.101. Novel Immuno-Oncology Biomarker Testing Market for Prostate Cancer, 2019-2030 (USD Million)
  • Table 16.102. Novel Immuno-Oncology Biomarker Testing Market for Other Cancer Indications, 2019-2030 (USD Million)
  • Table 16.103. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Disease Indication, 2019-2030 (Units, Million)
  • Table 16.104. Novel Immuno-Oncology Biomarker Testing Market for Blood Cancer, 2019-2030 (Units, Million)
  • Table 16.105. Novel Immuno-Oncology Biomarker Testing Market for Breast Cancer, 2019-2030 (Units, Million)
  • Table 16.106. Novel Immuno-Oncology Biomarker Testing Market for Colon Cancer, 2019-2030 (Units, Million)
  • Table 16.107. Novel Immuno-Oncology Biomarker Testing Market for Colorectal Cancer, 2019-2030 (Units, Million)
  • Table 16.108. Novel Immuno-Oncology Biomarker Testing Market for Lung Cancer, 2019-2030 (Units, Million)
  • Table 16.109. Novel Immuno-Oncology Biomarker Testing Market for Melanoma, 2019-2030 (Units, Million)
  • Table 16.110. Novel Immuno-Oncology Biomarker Testing Market for Prostate Cancer, 2019-2030 (Units, Million)
  • Table 16.111. Novel Immuno-Oncology Biomarker Testing Market for Other Cancer Indications, 2019-2030 (Units, Million)
  • Table 16.112. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Analytical Technique Used, 2019-2030 (USD Million)
  • Table 16.113. Novel Immuno-Oncology Biomarker Testing Market for Next Generation Sequencing, 2019-2030 (USD Million)
  • Table 16.114. Novel Immuno-Oncology Biomarker Testing Market for Polymerase Chain Reaction, 2019-2030 (USD Million)
  • Table 16.115. Novel Immuno-Oncology Biomarker Testing Market for Immunohistochemistry, 2019-2030 (USD Million)
  • Table 16.116. Novel Immuno-Oncology Biomarker Testing Market for Other Techniques Used, 2019-2030 (USD Million)
  • Table 16.117. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Analytical Technique Used, 2019-2030 (Units, Million)
  • Table 16.118. Novel Immuno-Oncology Biomarker Testing Market for Next Generation Sequencing, 2019-2030 (Units Million)
  • Table 16.119. Novel Immuno-Oncology Biomarker Testing Market for Polymerase Chain Reaction, 2019-2030 (Units Million)
  • Table 16.120. Novel Immuno-Oncology Biomarker Testing Market for Immunohistochemistry, 2019-2030 (Units Million)
  • Table 16.121. Novel Immuno-Oncology Biomarker Testing Market for Other Techniques Used, 2019-2030 (Units Million)
  • Table 16.122. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Application Area, 2019-2030 (USD Million)
  • Table 16.123. Novel Immuno-Oncology Biomarker Testing Market for Research Use, 2019-2030 (USD Million)
  • Table 16.124. Novel Immuno-Oncology Biomarker Testing Market for Clinical Use, 2019-2030 (USD Million)
  • Table 16.125. Novel Immuno-Oncology Biomarker Testing Market for Commercial Use, 2019-2030 (USD Million)
  • Table 16.126. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Application Area, 2019-2030 (Units, Million)
  • Table 16.127. Novel Immuno-Oncology Biomarker Testing Market for Research Use, 2019-2030 (Units, Million)
  • Table 16.128. Novel Immuno-Oncology Biomarker Testing Market for Clinical Use, 2019-2030 (Units, Million)
  • Table 16.129. Novel Immuno-Oncology Biomarker Testing Market for Commercial Use, 2019-2030 (Units, Million)
  • Table 16.130. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Geography, 2019-2030 (USD Million)
  • Table 16.131. Novel Immuno-Oncology Biomarker Testing Market in North America, 2019-2030 (USD Million)
  • Table 16.132. Novel Immuno-Oncology Biomarker Testing Market in Europe, 2019-2030 (USD Million)
  • Table 16.133. Novel Immuno-Oncology Biomarker Testing Market in Asia-Pacific, 2019-2030 (USD Million)
  • Table 16.134. Novel Immuno-Oncology Biomarker Testing Market in Rest of the World, 2019-2030 (USD Million)
  • Table 16.135. Global Novel Immuno-Oncology Biomarker Testing Market: Distribution by Geography, 2019-2030 (Units, Million)
  • Table 16.136. Novel Immuno-Oncology Biomarker Testing Market in North America, 2019-2030 (Units, Million)
  • Table 16.137. Novel Immuno-Oncology Biomarker Testing Market in Europe, 2019-2030 (Units, Million)
  • Table 16.138. Novel Immuno-Oncology Biomarker Testing Market in Asia-Pacific, 2019-2030 (Units, Million)
  • Table 16.139. Novel Immuno-Oncology Biomarker Testing Market in Rest of the World, 2019-2030 (Units, Million)
  • Table 16.140. Biomarker-based Clinical Trials of Big Pharmaceutical Companies: Cumulative Distribution by Trial Registration Year, 2016-2019
  • Table 16.141. Clinical Trial Analysis: Distribution by Trial Registration Year and Biomarker
  • Table 16.142. Clinical Trial Analysis: Distribution by Trial Registration Year and Disease Indication
  • Table 16.143. Clinical Trial Analysis: Distribution by Phase of Development
  • Table 16.144. Clinical Trial Analysis: Distribution by Trial Phase and Biomarker
  • Table 16.145. Clinical Trial Analysis: Distribution by Trial Phase and Disease Indication
  • Table 16.146. Clinical Trial Analysis: Distribution by Recruitment Status
  • Table 16.148. Clinical Trial Analysis: Distribution by Therapy Design
  • Table 16.149. Clinical Trial Analysis: Overall Distribution by Biomarkers
  • Table 16.150. Clinical Trial Analysis: Distribution by Type of Cancer Therapy
  • Table 16.151. Clinical Trial Analysis: Most Active Players
  • Table 16.152. Clinical Trial Analysis: Geographical Distribution by Number of Trials
  • Table 16.153. Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
  • Table 16.154. Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. AbbVie
  • 2. ACT Genomics
  • 3. Admera Health
  • 4. AITbiotech
  • 5. Ambry Genetics
  • 6. Amgen
  • 7. ARUP Laboratories
  • 8. Asper Biogene
  • 9. AstraZeneca
  • 10. Barbara Ann Karmanos Cancer Institute
  • 11. Bayer
  • 12. Biocartis
  • 13. Biodesix
  • 14. Biotype Innovation
  • 15. Boehringer Ingelheim
  • 16. Brigham and Women's Hospital
  • 17. Bristol-Myers Squibb
  • 18. Federal Association of German Pathologists
  • 19. Cancer Genetics
  • 20. Cancer Research Institute
  • 21. Cancer Treatment Centers of America
  • 22. Caprion Biosciences
  • 23. Caris Life Sciences
  • 24. CBLPath
  • 25. CeGaT
  • 26. Celator Pharmaceuticals (Subsidiary of Jazz Pharmaceuticals)
  • 27. Cell IDx
  • 28. CGC Genetics
  • 29. Chugai Pharmaceutical
  • 30. CIRCULOGENE
  • 31. City of Hope National Medical Center
  • 32. Clarient Diagnostic Services (Acquired by NeoGenomics Laboratories)
  • 33. Cofactor Genomics
  • 34. Columbia University
  • 35. Craig Hallum Capital Group
  • 36. CTOAM
  • 37. German Society of Pathology
  • 38. DIAN Diagnostics Group
  • 39. Dr Lal PathLabs
  • 40. EasyDNA
  • 41. Eli Lilly
  • 42. EMD Serono
  • 43. Epic Sciences
  • 44. European Organization for Research and Treatment of Cancer
  • 45. ExcellaBio
  • 46. Foundation Medicine
  • 47. Fox Chase Cancer Center
  • 48. Fred Hutchinson Cancer Research Center
  • 49. Genekor
  • 50. Genentech
  • 51. Genetron
  • 52. Genomics For Life
  • 53. Genoptix
  • 54. GenPath Diagnostics
  • 55. Gilead Sciences
  • 56. GlaxoSmithKline
  • 57. Gradalis
  • 58. Guardant Health
  • 59. HalioDx
  • 60. HistoGeneX
  • 61. Horizon Healthcare Services
  • 62. Illumina
  • 63. Immatics Biotechnologies
  • 64. Impact Genetics
  • 65. Innovent Biologics
  • 66. The Institute of Cancer Research, London
  • 67. Intermountain Healthcare
  • 68. Invitae
  • 69. IQVIA
  • 70. Johns Hopkins University
  • 71. Johnson & Johnson
  • 72. KEW
  • 73. KingMed Diagnostics
  • 74. LabCorp
  • 75. Lantheus Medical Imaging
  • 76. L.E.M laboratory
  • 77. Massachusetts General Hospital
  • 78. MD Anderson Cancer Center
  • 79. MedImmune
  • 80. Memorial Sloan Kettering Cancer Center
  • 81. Merck
  • 82. Metropolis
  • 83. Miltenyi Biotec
  • 84. MultiVir
  • 85. Nanostring Technologies
  • 86. NantHealth
  • 87. National Cancer Institute
  • 88. NEO New Oncology
  • 89. NeoGenomics Laboratories
  • 90. Novartis
  • 91. Novogene
  • 92. OmniSeq
  • 93. OncoDNA
  • 94. PathGroup
  • 95. PentaBase
  • 96. PerkinElmer
  • 97. Personal Genome Diagnostics
  • 98. Personalis
  • 99. Pfizer
  • 100. PhenoPath
  • 101. Positive Bioscience
  • 102. Promega
  • 103. Q2 Solutions
  • 104. QIAGEN
  • 105. Quality Assurance Initiative Pathology
  • 106. Quest Diagnostics
  • 107. Regeneron Pharmaceuticals
  • 108. Roche
  • 109. Roswell Park Cancer Institute
  • 110. Sanofi
  • 111. Sarah Cannon Research Institute
  • 112. SeraCare Life Sciences
  • 113. Shanghai HAORAN Biotechnology
  • 114. Shenzhen Yuce Biotechnology
  • 115. Sidney Kimmel Comprehensive Cancer Center
  • 116. Sun Yat-sen University
  • 117. Sysmex
  • 118. Takeda Pharmaceutical
  • 119. Tempus
  • 120. The Netherlands Cancer Institute
  • 121. Thermo Fisher Scientific
  • 122. UNICANCER
  • 123. University of Pittsburgh
  • 124. University of Washington
  • 125. Ventana Medical Systems
  • 126. Viapath
  • 127. Wake Forest University Health Sciences
Back to Top